Clinical Trial Update: Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics [Phase 3]

View source ↗

Summary

A Phase 3 immunogenicity trial of Wockhardt's insulin lispro/lispro mix basal-bolus regimen for Type 1 diabetes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Insulin lispro mix (insulin lispro mix)
• insulin lispro (insulin lispro)

Snippet

Sponsor: Wockhardt | Conditions: Type I Diabetes | Phase 3 | Status: WITHDRAWN